Joelle Helou1, Isabelle Thibault2, William Chu3, Pablo Munoz-Schuffenegger1, Darby Erler3, George Rodrigues4, Andrew Warner4, Kelvin K W Chan5, Edward Chow3, Renee Korol3, Melanie Davidson3, Hans T Chung6. 1. Department of Radiation Oncology, University of Toronto, Princess Margaret Cancer Centre, Canada. 2. Department of Radiation Oncology, Université de Laval, Centre Hospitalier Universitaire de Quebec, Canada. 3. Department of Radiation Oncology, University of Toronto, Sunnybrook Odette Cancer Centre, Canada. 4. Division of Radiation Oncology, Department of Oncology, Western University and London Regional Cancer Program, London, Ontario, Canada. 5. Department of Medicine, University of Toronto, Canada; Division of Medical Oncology, Sunnybrook Odette Cancer Centre, Canada; Canadian Centre for Applied Research in Cancer Control (ARCC), Canada. 6. Department of Radiation Oncology, University of Toronto, Sunnybrook Odette Cancer Centre, Canada. Electronic address: Hans.Chung@sunnybrook.ca.
Abstract
PURPOSE: To report the changes in quality of life (QoL) after stereotactic ablative radiotherapy (SABR) in patients with liver metastases (LM). MATERIALS AND METHODS: A prospective cohort study was undertaken to measure the acute changes in QoL after SABR. Patients with 1-3 treated LM were eligible. Doses of 30-60 Gy in 3-5 fractions were delivered. Prospective QoL was measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires, Core 15 for Palliative Care (EORTC QLQ-C15-PAL) and liver metastases (LM21), at baseline, 1st week and last day of treatment, then 1, 6 and 12 weeks after SABR. The functional living index-emesis (FLIE) was collected at baseline, 1st week, last day and 1 week after treatment. Univariable and multivariable linear mixed modeling were performed as appropriate to assess changes in QoL over time. RESULTS: Sixty patients were included. The most common primary cancer was colorectal (42%). The global health score measured by QLQ-C15-PAL was significantly worse at treatment completion (p = 0.001), 1 week (p = 0.003) and 6 weeks (p = 0.002) after SABR but recovered by 12 weeks (p = 0.124). Nausea and constipation were worse at treatment completion (p < 0.05) but recovered 1 week after while fatigue recovered 6 weeks post-SABR. The majority of patients reported stable QoL at 12 weeks for all domains in the C15-PAL and LM21 questionnaires. CONCLUSION: SABR offers a non-invasive mean of ablating LM with minimal impact on acute QoL.
PURPOSE: To report the changes in quality of life (QoL) after stereotactic ablative radiotherapy (SABR) in patients with liver metastases (LM). MATERIALS AND METHODS: A prospective cohort study was undertaken to measure the acute changes in QoL after SABR. Patients with 1-3 treated LM were eligible. Doses of 30-60 Gy in 3-5 fractions were delivered. Prospective QoL was measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires, Core 15 for Palliative Care (EORTC QLQ-C15-PAL) and liver metastases (LM21), at baseline, 1st week and last day of treatment, then 1, 6 and 12 weeks after SABR. The functional living index-emesis (FLIE) was collected at baseline, 1st week, last day and 1 week after treatment. Univariable and multivariable linear mixed modeling were performed as appropriate to assess changes in QoL over time. RESULTS: Sixty patients were included. The most common primary cancer was colorectal (42%). The global health score measured by QLQ-C15-PAL was significantly worse at treatment completion (p = 0.001), 1 week (p = 0.003) and 6 weeks (p = 0.002) after SABR but recovered by 12 weeks (p = 0.124). Nausea and constipation were worse at treatment completion (p < 0.05) but recovered 1 week after while fatigue recovered 6 weeks post-SABR. The majority of patients reported stable QoL at 12 weeks for all domains in the C15-PAL and LM21 questionnaires. CONCLUSION:SABR offers a non-invasive mean of ablating LM with minimal impact on acute QoL.
Authors: Felix G Gassert; Johannes Rübenthaler; Clemens C Cyran; Johann S Rink; Vincent Schwarze; Johanna Luitjens; Florian T Gassert; Marcus R Makowski; Stefan O Schoenberg; Marius E Mayerhoefer; Dietmar Tamandl; Matthias F Froelich Journal: Eur J Nucl Med Mol Imaging Date: 2021-03-09 Impact factor: 9.236